{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:11:23Z","timestamp":1783512683683,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470368"],"award-info":[{"award-number":["81470368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670187"],"award-info":[{"award-number":["81670187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81641011"],"award-info":[{"award-number":["81641011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7152030"],"award-info":[{"award-number":["7152030"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7172047"],"award-info":[{"award-number":["7172047"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3760-0","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T06:06:46Z","timestamp":1510294006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP"],"prefix":"10.1186","volume":"17","author":[{"given":"Yalu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"issue":"3","key":"3760_CR1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357\u201365.","journal-title":"Nat Genet"},{"issue":"2","key":"3760_CR2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ijc.11548","volume":"108","author":"D Pim","year":"2004","unstructured":"Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196\u20139.","journal-title":"Int J Cancer"},{"issue":"25","key":"3760_CR3","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1038\/sj.onc.1209405","volume":"25","author":"M Siddique","year":"2006","unstructured":"Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25(25):3489\u2013500.","journal-title":"Oncogene"},{"issue":"2","key":"3760_CR4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/MCB.19.2.1092","volume":"19","author":"M Thomas","year":"1999","unstructured":"Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092\u2013100.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"3760_CR5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.canep.2010.06.013","volume":"34","author":"LA Henriquez-Hernandez","year":"2010","unstructured":"Henriquez-Hernandez LA, Murias-Rosales A, Gonzalez-Hernandez A, de Leon AC, Diaz-Chico N, Fernandez-Perez L. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol. 2010;34(5):634\u20138.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"3760_CR6","first-page":"3198","volume":"8","author":"JY Ru","year":"2015","unstructured":"Ru JY, Cong Y, Kang WB, Yu L, Guo T, Zhao JN. Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population. Int J Clin Exp Pathol. 2015;8(3):3198\u2013203.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"3760_CR7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.18632\/oncotarget.13589","volume":"8","author":"X Tian","year":"2017","unstructured":"Tian X, Dai SD, Sun J, Jiang SY, Jiang YH. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: an updated meta-analysis based on 32 studies. Oncotarget. 2017;8(1):1156\u2013U1969.","journal-title":"Oncotarget"},{"key":"3760_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcmd.2016.05.007","volume":"59","author":"N Weich","year":"2016","unstructured":"Weich N, Ferri C, Moiraghi B, Bengio R, Giere I, Pavlovsky C, Larripa I, Fundia A. TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome. Blood Cell Mol Dis. 2016;59:129\u201333.","journal-title":"Blood Cell Mol Dis"},{"key":"3760_CR9","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/S0016672315000075","volume":"97","author":"MH Khan","year":"2015","unstructured":"Khan MH, Khalil A, Rashid H. Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis. Genet Res (Camb). 2015;97:e7.","journal-title":"Genet Res (Camb)"},{"issue":"4","key":"3760_CR10","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.25710","volume":"129","author":"G Francisco","year":"2011","unstructured":"Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer. 2011;129(4):920\u201330.","journal-title":"Int J Cancer"},{"issue":"10","key":"3760_CR11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ajh.21834","volume":"85","author":"HN Kim","year":"2010","unstructured":"Kim HN, Yu L, Kim NY, Lee IK, Kim YK, Yang DH, Lee JJ, Shin MH, Park KS, Choi JS, et al. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol. 2010;85(10):822\u20134.","journal-title":"Am J Hematol"},{"issue":"9","key":"3760_CR12","doi-asserted-by":"crossref","first-page":"e107047","DOI":"10.1371\/journal.pone.0107047","volume":"9","author":"C Fan","year":"2014","unstructured":"Fan C, Wei J, Yuan C, Wang X, Jiang C, Zhou C, Yang M. The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to non-Hodgkin lymphoma risk. PLoS One. 2014;9(9):e107047.","journal-title":"PLoS One"},{"issue":"9","key":"3760_CR13","doi-asserted-by":"crossref","first-page":"e45820","DOI":"10.1371\/journal.pone.0045820","volume":"7","author":"Y Weng","year":"2012","unstructured":"Weng Y, Lu L, Yuan G, Guo J, Zhang Z, Xie X, Chen G, Zhang J. p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One. 2012;7(9):e45820.","journal-title":"PLoS One"},{"issue":"5","key":"3760_CR14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/10428190310001638878","volume":"45","author":"A Hishida","year":"2004","unstructured":"Hishida A, Matsuo K, Tajima K, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Naoe T, Hamajima N. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma. 2004;45(5):957\u201364.","journal-title":"Leuk Lymphoma"},{"key":"3760_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-8-116","volume":"8","author":"J Bittenbring","year":"2008","unstructured":"Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschenmeyer L, Kreuz M, Truemper L, Landt O, Menzel A, Pfreundschuh M, et al. MDM2 gene SNP309 T\/G and p53 gene SNP72 G\/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer. 2008;8:116.","journal-title":"BMC Cancer"},{"issue":"1","key":"3760_CR16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.13533","volume":"94","author":"D Wrench","year":"2009","unstructured":"Wrench D, Waters R, Carlotti E, Iqbal S, Matthews J, Calaminici M, Gribben J, Lister TA, Fitzgibbon J. Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. Haematologica. 2009;94(1):148\u201350.","journal-title":"Haematologica"},{"issue":"4","key":"3760_CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"3760_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613\u201326.","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"3760_CR19","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreundschuh M, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325.","journal-title":"Ann Oncol"},{"issue":"3","key":"3760_CR20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.6004\/jnccn.2013.0037","volume":"11","author":"AD Zelenetz","year":"2013","unstructured":"Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, et al. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Cancer Netw. 2013;11(3):257\u201372. quiz 273","journal-title":"J Natl Compr Cancer Netw"},{"key":"3760_CR21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","volume":"7","author":"T Suresh","year":"2014","unstructured":"Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7:58.","journal-title":"J Hematol Oncol"},{"key":"3760_CR22","doi-asserted-by":"crossref","unstructured":"Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007:233\u201342.","DOI":"10.1182\/asheducation-2007.1.233"},{"issue":"3","key":"3760_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","volume":"10","author":"RL Elstrom","year":"2010","unstructured":"Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3760_CR24","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-10-2573","volume":"17","author":"LM Rimsza","year":"2011","unstructured":"Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook JR, et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res. 2011;17(11):3727\u201332.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3760_CR25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"5","key":"3760_CR26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3760_CR27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol. 1999;17(4):1244.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3760_CR28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634\u201341.","journal-title":"Blood"},{"issue":"3","key":"3760_CR29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626\u201333.","journal-title":"Blood"},{"issue":"11","key":"3760_CR30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3760_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3760_CR32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379\u201391.","journal-title":"Lancet Oncol"},{"issue":"19","key":"3760_CR33","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/sj.onc.1207428","volume":"23","author":"A Sullivan","year":"2004","unstructured":"Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23(19):3328\u201337.","journal-title":"Oncogene"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T19:59:00Z","timestamp":1570305540000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3760-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3760"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3760-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]},"article-number":"743"}}